CellaVision AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLVSF research report →
Price Chart
About the company
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations.
- CEO
- Steve Ferguson
- IPO
- 2013
- Employees
- 251
- HQ
- Lund, SN, SE
Get TickerSpark's AI analysis on CLVSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $470.83M
- P/E
- 34.86
- Fwd P/E
- 3.20
- PEG
- -3.88
- P/S
- 6.30
- P/B
- 5.15
- EV/EBITDA
- 22.13
- Div Yield
- 1.36%
- Gross Margin
- 68.01%
- Op Margin
- 22.97%
- Net Margin
- 18.08%
- ROE
- 15.24%
- ROIC
- 12.88%
Latest fiscal year · YoY change
- Revenue
- $758.97M+4.9%
- Gross Profit
- $519.88M+6.7%
- Op Income
- $202.07M
- Net Income
- $153.08M+8.8%
- EPS
- $6.42+8.8%
- OCF Growth
- +1.1%
- FCF Growth
- -5.3%
- 52W High
- $20.83
- 52W Low
- $13.49
- 50D MA
- $15.57
- 200D MA
- $14.80
- Beta
- 0.87
- RSI (14)
- 75
- Avg Volume
- 9
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CellaVision delivered solid Q3 growth with higher sales, strong Americas and APAC momentum, and continued progress on new product launches and the strategy reset.· October 29, 2026
- Net sales rose 13.6% to SEK 200 million, with 13.4% organic growth and only a minor currency effect.
- EBITDA was SEK 64 million, equal to a 32% margin, while gross margin was 66%.
- Americas grew 32% to SEK 89 million on demand for large connected platforms, including a significant Canada tender win.
- APAC grew 91% organically, driven by broad-based growth outside China and stronger reagent conversion in Japan.
- EMEA was down 10% year over year, but management said underlying sales improved sequentially and Bone Marrow Aspirate has begun generating first revenue.
Q3 net sales were SEK 200 million, up 13.6% year over year and 13.4% organically. Gross margin was 66%, versus lower pressure from SEK 5 million of amortization tied to bone marrow and upgraded software development, compared with SEK 2 million last year, plus a negative sales mix effect. EBITDA was SEK 64 million, representing a 32% margin. Operating expenses were SEK 82 million, or 41% of sales; R&D before capitalization was SEK 39 million, with SEK 16 million capitalized, resulting in reported R&D cost of SEK 23 million. Operating cash flow was SEK 68 million, cash flow was SEK 46 million, and cash and cash equivalents were SEK 219 million. No explicit full-year or next-quarter financial guidance was given, but management said the FDA 510(k) review is ongoing and the aim is to obtain U.S. clearance before year-end; they also said amortization should stay at this level until the next product launch.
Steve Ferguson emphasized that the quarter showed broad commercial execution, especially in Americas and APAC, and called the Bone Marrow Aspirate launch a meaningful milestone as it moved from evaluation to first revenue in EMEA. He also highlighted continued progress on FPM technology and next-generation hematology analyzers, describing the platform as a step forward for digital cell morphology with potential expansion into pathology and cytology. His tone was confident but measured, with repeated comments that the business is navigating healthcare budget pressure and that the new strategy will be laid out at the February 17 Capital Markets Day.
Monica Jonsson said the quarter’s 66% gross margin reflected both higher amortization and a weaker mix, with amortization rising to SEK 5 million from SEK 2 million last year due to capitalized development costs. She noted operating expenses of SEK 82 million, including SEK 4 million tied to the final settlement of the CEO transition, and said R&D before capitalization was SEK 39 million while capitalized R&D was SEK 16 million. Cash generation remained strong, with operating cash flow of SEK 68 million, cash flow of SEK 46 million, and SEK 219 million in cash and cash equivalents on the balance sheet. She also said price increases came into effect from Q2 and were roughly in line with inflation, and that R&D spending should be closer to 20%–21% of sales going forward versus 19% in Q3.
Analysts focused on price increases, gross margin pressure, Americas sustainability, EMEA recovery, reagent demand, R&D run rate, and APAC timing. Management said price increases were introduced in Q2 and are now fully visible, while gross margin should remain pressured by amortization until the next product launch, with sales mix varying naturally quarter to quarter. On Americas, Steve Ferguson said demand for connected lab solutions remains high and the region still looks like a growth case, helped by a strong relationship with the partner and good visibility. On APAC, management said growth was broad-based outside China, driven mainly by commercial execution and the reagent value proposition in Japan, with no unusual timing effects noted.
The call showed strong momentum in two key growth regions: Americas rose 32% and APAC 91% organically, while reagent revenue and software also grew. Management sounded confident that connected lab solutions, reagent conversions, and the Bone Marrow Aspirate rollout can keep supporting recurring revenue and future expansion.
EMEA remained down 10% year over year, China was described as under pressure from healthcare cost controls, and broader European markets were also said to be seeking more value for money. Gross margin is being held down by amortization tied to recent development spending, and management said that pressure will persist until the next product launch.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 58.9%
- Shares Outstanding
- 23.85M
- Float Shares
- 14.04M
Our CLVSF coverage
Recent articles, reports, and earnings notes.
No research on CLVSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLVSF report →CellaVision AB (publ) (CLVSF) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
CellaVision AB (publ) (CLVSF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 17
CellaVision AB (publ) (CLVSF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 5
CellaVision AB (publ) (CLVSF) Q3 2025 Earnings Call Transcript
seekingalpha.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.